Implandata Ophthalmic Products announced the launch of its web-based Eyemate IOP-Tracking Service for remote monitoring and management of glaucoma. The Eyemate provides eye doctors with IOP measurements collected anytime under patients’ normal life conditions.
“Remote IOP monitoring provides immediate alert in case the therapy needs to be adjusted, without requiring an office visit,” Prof. Kaweh Mansouri, MD, Ophthalmologist at Clinique de Montchoisi Lausanne/Switzerland and Chief Medical Officer of Implandata, said in a company news release. “This is vital for controlling glaucoma, because IOP fluctuates continually without patients noticing it. The need for remote monitoring is even greater during stay-at-home orders, as we’re experiencing due to COVID-19; we can ensure that glaucoma care is well managed, without putting patients at risk.”
“Remote monitoring of IOP will transform glaucoma care,” Prof. Robert N. Weinreb MD, Chair and Distinguished Professor of Ophthalmology at the University of California, San Diego, said in the news release. “The availability of large amounts of real-life IOP data will enable personalized glaucoma management to prevent vision loss.”
The CE-marked Eyemate system is now offered to patients by eye centers in Germany, Switzerland and the UK. Further eye clinics are on the Eyemate waiting list. The FDA Breakthrough Device approval process has been started, in preparation for launching the Eyemate system in the US.